BCL11B targeting in tumor CD8 ⁺ T cells amplifies anti-tumor response by blocking exhaustion while promoting stemness...

Tumor infiltrating CD8 ⁺ T cells (TILs) progress to a state of terminal exhaustion (Ttex) which have impaired functionality and are nonrenewable. However their precursors (Tpex) are renewable and can generate efficient effector cells. We started from the observation that melanoma patients undergoing therapy with checkpoint inhibitors show increased survival when their T cells have low BCL11B mRNA. In line with this, ablation of Bcl11b in CD8 ⁺ TILs conferred a superior anti-tumor response in murine melanoma and ovarian cancer models. Bcl11b KO TILs failed to progress to the Ttex state and retained elevated stemness. Bcl11b exerted its role by repressing expression of essential transcription factors (TF) controlling stemness, and conversely by promoting expression of exhaustion-associated TFs and inhibitory receptor genes, through complex epigenetic control. In addition, Bcl11b KO CD8 ⁺ T cells showed increased Ag-specific cytolytic activity and elevated Gzmb and Prf1 proteins, but no increase in their mRNAs, however presented higher expression of genes with role in translation. Furthermore, CRISPR-CAS9-mediated deletion of BCL11B in human TILs from a patient with poor response to adoptive cell therapy with autologous TILs, improved their cytolytic activity and promoted expression of the stemness-associated TF TCF1, underlying its potential therapeutic use.

Adoptive transfer of Bcl11b KO CD8 ⁺ TILs surpasses WT in tumor burden reduction Bcl11b ablation reprograms TILs and impairs the progression to Ttex state Bcl11b KO CD8 ⁺ T cells have elevated cytotoxicity and kill only Ag-MHCI targets BCL11B deletion in nonresponder ACT-TIL improves cytolytic activity and elevates TCF1.